## Mariaelvina Sala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2065062/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K). Molecular Autism, 2022, 13, 1.	2.6	10
2	Increased Response to 3,4-Methylenedioxymethamphetamine (MDMA) Reward and Altered Gene Expression in Zebrafish During Short- and Long-Term Nicotine Withdrawal. Molecular Neurobiology, 2021, 58, 1650-1663.	1.9	5
3	Altered mRNA Levels of Stress-Related Peptides in Mouse Hippocampus and Caudate-Putamen in Withdrawal after Long-Term Intermittent Exposure to Tobacco Smoke or Electronic Cigarette Vapour. International Journal of Molecular Sciences, 2021, 22, 599.	1.8	9
4	Developmental impaired Akt signaling in the Shank1 and Shank3 double knock-out mice. Molecular Psychiatry, 2021, 26, 1928-1944.	4.1	26
5	The DNA repair protein ATM as a target in autism spectrum disorder. JCI Insight, 2021, 6, .	2.3	13
6	Arhgap22 Disruption Leads to RAC1 Hyperactivity Affecting Hippocampal Glutamatergic Synapses and Cognition in Mice. Molecular Neurobiology, 2021, 58, 6092-6110.	1.9	4
7	Conservation of mechanisms regulating emotional-like responses on spontaneous nicotine withdrawal in zebrafish and mammals. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110334.	2.5	8
8	Ultrastructural Evidence for a Role of Astrocytes and Glycogen-Derived Lactate in Learning-Dependent Synaptic Stabilization. Cerebral Cortex, 2020, 30, 2114-2127.	1.6	44
9	LSD1 is an environmental stress-sensitive negative modulator of the glutamatergic synapse. Neurobiology of Stress, 2020, 13, 100280.	1.9	10
10	Acute DOB and PMA Administration Impairs Motor and Sensorimotor Responses in Mice and Causes Hallucinogenic Effects in Adult Zebrafish. Brain Sciences, 2020, 10, 586.	1.1	6
11	Persistent cognitive and affective alterations at late withdrawal stages after long-term intermittent exposure to tobacco smoke or electronic cigarette vapour: Behavioural changes and their neurochemical correlates. Pharmacological Research, 2020, 158, 104941.	3.1	12
12	Behavioural and pharmacological profiles of zebrafish administrated pyrrolidinyl benzodioxanes and prolinol aryl ethers with high affinity for heteromeric nicotinic acetylcholine receptors. Psychopharmacology, 2020, 237, 2317-2326.	1.5	11
13	Impaired approach to novelty and striatal alterations in the oxytocin receptor deficient mouse model of autism. Hormones and Behavior, 2019, 114, 104543.	1.0	12
14	Linking NMDA Receptor Synaptic Retention to Synaptic Plasticity and Cognition. IScience, 2019, 19, 927-939.	1.9	31
15	Different attentional dysfunctions in <i>eEF2K</i> <sup><i>â^'/â^'</i></sup> <i>, IL1RAPL1</i> <sup><i>â^'/â^'</i></sup> and <i>SHANK3Δ11</i> <sup><i>â^'/â^'</i></sup> mice. Genes, Brain and Behavior, 2019, 18, e12563.	1.1	7
16	Increased sensitivity to Δ9-THC-induced rewarding effects after seven-week exposure to electronic and tobacco cigarettes in mice. European Neuropsychopharmacology, 2019, 29, 566-576.	0.3	14
17	In vivo and in vitro ADMET profiling and in vivo pharmacodynamic investigations of a selective α7 nicotinic acetylcholine receptor agonist with a spirocyclic Δ 2 -isoxazoline molecular skeleton. European Journal of Pharmacology, 2018, 820, 265-273.	1.7	12
18	Visual Object Recognition Task. Handbook of Behavioral Neuroscience, 2018, 27, 139-150.	0.7	0

#	Article	IF	CITATIONS
19	eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures. Cerebral Cortex, 2017, 27, bhw075.	1.6	57
20	Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice. Molecular Psychiatry, 2017, 22, 689-702.	4.1	134
21	Fingolimod Limits Acute Aβ Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal Neurons. Scientific Reports, 2017, 7, 41734.	1.6	27
22	Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission. Nature Communications, 2017, 8, 14536.	5.8	31
23	Homer1b/c clustering is impaired in Phelan-McDermid Syndrome iPSCs derived neurons. Molecular Psychiatry, 2017, 22, 637-637.	4.1	4
24	The X-Linked Intellectual Disability Protein IL1RAPL1 Regulates Dendrite Complexity. Journal of Neuroscience, 2017, 37, 6606-6627.	1.7	36
25	Pharmacological Modulation of AMPAR Rescues Intellectual Disability-Like Phenotype in Tm4sf2â <sup>~,</sup> /y Mice. Cerebral Cortex, 2017, 27, 5369-5384.	1.6	33
26	The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish. Frontiers in Psychiatry, 2017, 8, 146.	1.3	5
27	Myosin IXa Binds AMPAR and Regulates Synaptic Structure, LTP, and Cognitive Function. Frontiers in Molecular Neuroscience, 2016, 9, 1.	1.4	61
28	Zebrafish: An Animal Model to Study Nicotinic Drugs on Spatial Memory and Visual Attention. Neuromethods, 2016, , 33-50.	0.2	0
29	Ritanserin-sensitive receptors modulate the prosocial and the anxiolytic effect of MDMA derivatives, DOB and PMA, in zebrafish. Behavioural Brain Research, 2016, 314, 181-189.	1.2	21
30	Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure. Journal of Medicinal Chemistry, 2016, 59, 7152-7166.	2.9	49
31	Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors. Psychopharmacology, 2016, 233, 3031-3039.	1.5	10
32	LSD1 modulates stress-evoked transcription of immediate early genes and emotional behavior. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3651-3656.	3.3	70
33	Different attentional abilities among inbred mice strains using virtual object recognition task (VORT): SNAP25+/â^' mice as a model of attentional deficit. Behavioural Brain Research, 2016, 296, 393-400.	1.2	10
34	Association between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategies. Translational Psychiatry, 2015, 5, e500-e500.	2.4	76
35	Spontaneous object and movement representations in 4-month-old human infants and albino Swiss mice. Cognition, 2015, 137, 63-71.	1.1	4
36	Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice. European Neuropsychopharmacology, 2015, 25, 1775-1786.	0.3	76

#	Article	IF	CITATIONS
37	LSD1 Neurospecific Alternative Splicing Controls Neuronal Excitability in Mouse Models of Epilepsy. Cerebral Cortex, 2015, 25, 2729-2740.	1.6	51
38	The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors. Psychopharmacology, 2014, 231, 4681-4693.	1.5	28
39	Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish. Psychopharmacology, 2014, 231, 1975-1985.	1.5	61
40	A new model to study visual attention in zebrafish. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 55, 80-86.	2.5	48
41	Epileptiform Activity and Cognitive Deficits in SNAP-25+/â^' Mice are Normalized by Antiepileptic Drugs. Cerebral Cortex, 2014, 24, 364-376.	1.6	78
42	Learning About Oxytocin: Pharmacologic and Behavioral Issues. Biological Psychiatry, 2014, 76, 360-366.	0.7	65
43	Mice discriminate between stationary and moving 2D shapes: Application to the object recognition task to increase attention. Behavioural Brain Research, 2013, 242, 95-101.	1.2	21
44	Cytoarchitectural, behavioural and neurophysiological dysfunctions in the <scp>BCNU</scp> â€ŧreated rat model of cortical dysplasia. European Journal of Neuroscience, 2013, 37, 150-162.	1.2	13
45	Mice Heterozygous for the Oxytocin Receptor Gene ( <i>Oxtr</i> <sup><i>+/â^²</i></sup> ) Show Impaired Social Behaviour but not Increased Aggression or Cognitive Inflexibility: Evidence of a Selective Haploinsufficiency Gene Effect. Journal of Neuroendocrinology, 2013, 25, 107-118.	1.2	92
46	<scp>CC</scp> 4, a dimer of cytisine, is a selective partial agonist at î±4î²2/î±6î²2 <scp>nAChR</scp> with improved selectivity for tobacco smoking cessation. British Journal of Pharmacology, 2013, 168, 835-849.	2.7	31
47	Eps8 controls dendritic spine density and synaptic plasticity through its actin-capping activity. EMBO Journal, 2013, 32, 1730-1744.	3.5	54
48	Neurohypophyseal hormones protect against pentylenetetrazole-induced seizures in zebrafish: Role of oxytocin-like and V1a-like receptor. Peptides, 2012, 37, 327-333.	1.2	17
49	Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish. Psychopharmacology, 2012, 220, 319-330.	1.5	85
50	Pharmacologic Rescue of Impaired Cognitive Flexibility, Social Deficits, Increased Aggression, and Seizure Susceptibility in Oxytocin Receptor Null Mice: A Neurobehavioral Model of Autism. Biological Psychiatry, 2011, 69, 875-882.	0.7	315
51	Learning and Memory Impairment Induced by Salvinorin A, the Principal Ingredient of <i>Salvia divinorum</i> , in Wistar Rats. International Journal of Toxicology, 2011, 30, 650-661.	0.6	25
52	Pharmacokinetics and distribution of clioquinol in golden hamstersâ€. Journal of Pharmacy and Pharmacology, 2010, 59, 387-393.	1.2	11
53	Cognitive memory control in borderline personality disorder patients. Psychological Medicine, 2009, 39, 845-853.	2.7	19
54	Expression of mutant β2 nicotinic receptors during development is crucial for epileptogenesis. Human Molecular Genetics, 2009, 18, 1075-1088.	1.4	37

#	Article	IF	CITATIONS
55	Effects of clioquinol on memory impairment and the neurochemical modifications induced by scrapie infection in golden hamsters. Brain Research, 2009, 1280, 195-200.	1.1	17
56	Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus, 2009, 19, 763-772.	0.9	244
57	The Depressive Phenotype Induced in Adult Female Rats by Adolescent Exposure to THC is Associated with Cognitive Impairment and Altered Neuroplasticity in the Prefrontal Cortex. Neurotoxicity Research, 2009, 15, 291-302.	1.3	117
58	SNAPâ€⊋5 in Neuropsychiatric Disorders. Annals of the New York Academy of Sciences, 2009, 1152, 93-99.	1.8	98
59	Potential anxiolytic―and antidepressantâ€ŀike effects of salvinorin A, the main active ingredient of <i>Salvia divinorum</i> , in rodents. British Journal of Pharmacology, 2009, 157, 844-853.	2.7	113
60	Involvement of κ-Opioid and Endocannabinoid System on Salvinorin A-Induced Reward. Biological Psychiatry, 2008, 63, 286-292.	0.7	89
61	Chronic Δ9-Tetrahydrocannabinol During Adolescence Provokes Sex-Dependent Changes in the Emotional Profile in Adult Rats: Behavioral and Biochemical Correlates. Neuropsychopharmacology, 2008, 33, 2760-2771.	2.8	304
62	Diazepam Protects Against the Enhanced Toxicity of Cocaine Adulterated With Atropine. Journal of Pharmacological Sciences, 2008, 107, 408-418.	1.1	4
63	Cellular Mechanisms Underlying the Anxiolytic Effect of Low Doses of Peripheral Δ9-Tetrahydrocannabinol in Rats. Neuropsychopharmacology, 2007, 32, 2036-2045.	2.8	115
64	Δ <sup>9</sup> â€Tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. British Journal of Pharmacology, 2007, 152, 1301-1311.	2.7	34
65	5-HT1A receptors are involved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague–Dawley rats. European Journal of Pharmacology, 2007, 555, 156-163.	1.7	100
66	Hallucinatory and rewarding effect of salvinorin A in zebrafish: κ-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology, 2007, 190, 441-448.	1.5	122
67	Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. British Journal of Pharmacology, 2006, 147, 552-559.	2.7	66
68	Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. British Journal of Pharmacology, 2005, 144, 727-735.	2.7	84
69	Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacology Biochemistry and Behavior, 2005, 81, 407-416.	1.3	28
70	3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacological Research, 2005, 51, 177-182.	3.1	56
71	16 Predominant Breastfeeding in The Maternity Ward and Infant's Feeding Practices Through The First Year of Life. Pediatric Research, 2004, 56, 466-466.	1.1	0
72	Δ9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. European Journal of Pharmacology, 2004, 506, 63-69.	1.7	132

#	Article	IF	CITATIONS
73	In vivo Model for the Evaluation of Molecules Active Towards Transmissible Spongiform Encephalopathies. Veterinary Research Communications, 2004, 28, 307-310.	0.6	7
74	Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (Cambridge), 2004, 131, 3805-3819.	1.2	587
75	Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behavioural Brain Research, 2004, 153, 423-429.	1.2	144
76	Neurochemical and behavioural modifications induced by scrapie infection in golden hamsters. Brain Research, 2003, 984, 237-241.	1.1	9
77	Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neuroscience Letters, 2003, 346, 61-64.	1.0	66
78	3,4 Methylenedioxymethamphetamine (ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats Behavioral Neuroscience, 2002, 116, 298-304.	0.6	21
79	Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. British Journal of Pharmacology, 2002, 136, 1089-1092.	2.7	52
80	3,4 Methylenedioxymethamphetamine (ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats Behavioral Neuroscience, 2002, 116, 298-304.	0.6	13
81	Involvement of CDC25Mm/Ras-GRF1-Dependent Signaling in the Control of Neuronal Excitability. Molecular and Cellular Neurosciences, 2001, 18, 691-701.	1.0	26
82	Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience, 2001, 104, 923-926.	1.1	144
83	Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. European Journal of Pharmacology, 2001, 413, 227-234.	1.7	107
84	Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat. European Journal of Pharmacology, 2001, 426, 193-200.	1.7	61
85	Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies. CNS Neuroscience & Therapeutics, 2001, 7, 369-386.	4.0	31
86	Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats. NeuroReport, 2000, 11, 2025-2029.	0.6	51
87	In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: Behavioral and cellular responses after acute and chronic treatments. , 2000, 35, 8-14.		46
88	CP 55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotionin Mongolian gerbils. Neuroscience Letters, 2000, 296, 69-72.	1.0	40
89	EXCITATORY AND INHIBITORY EFFECTS OF SECOND-GENERATION CHOLINESTERASE INHIBITORS ON RAT GASTROINTESTINAL TRANSIT. Pharmacological Research, 2000, 41, 671-677.	3.1	4
90	Eptastigmine improves eight-arm radial maze performance in aged rats. Pharmacological Research, 2000, 42, 299-304.	3.1	14

#	Article	IF	CITATIONS
91	Eptastigmine restores the aged rat's normal cortical spectral power pattern. Pharmacological Research, 2000, 42, 495-500.	3.1	6
92	Long-Lasting Antiamnesic Effect of a Novel Anticholinesterase Inhibitor (MF268). Pharmacology Biochemistry and Behavior, 1998, 59, 897-901.	1.3	15
93	A novel method for self-administering addicting drugs intracerebroventricularly in a free-choice procedure. Brain Research Protocols, 1998, 3, 135-141.	1.7	7
94	Polydeoxyribonucleotide (defibrotide) protects against post-ischemic behavioral, electroencephalographic and neuronal damage in the gerbil. European Journal of Pharmacology, 1997, 328, 143-152.	1.7	14
95	Naltrexone, Naltrindole, and CTOP Block Cocaine-Induced Sensitization to Seizures and Death. Peptides, 1997, 18, 1189-1195.	1.2	11
96	An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. European Journal of Pharmacology, 1996, 302, 13-20.	1.7	97
97	Different kinetics of tolerance to behavioral and electroencephalographic effects of chlordiazepoxide in the rat. European Journal of Pharmacology, 1995, 273, 35-45.	1.7	10
98	Eeg power spectra and behavioural correlates in rats given chronic morphine. lack of residual long-term eeg and neuronal changes. Pharmacological Research, 1995, 32, 95-103.	3.1	8
99	Behavioral and biochemical evidence of opioidergic involvement in cocaine sensitization. Journal of Pharmacology and Experimental Therapeutics, 1995, 274, 450-7.	1.3	36
100	Influence of opioid system on behavioral sensitization induced by cocaine in the rat. Regulatory Peptides, 1994, 53, S199-S200.	1.9	1
101	Relationship between morphine and etonitazene-induced working memory impairment and analgesia. European Journal of Pharmacology, 1994, 271, 497-504.	1.7	26
102	Chronic morphine affects working memory during treatment and withdrawal in rats. Behavioural Pharmacology, 1994, 5, 570-580.	0.8	48
103	Possibility of Spontaneous Drug Abuse Tested in Rat. Pharmacological Research, 1993, 28, 21-34.	3.1	1
104	Dose-dependent conditioned place preference produced by etonitazene and morphine. European Journal of Pharmacology, 1992, 217, 37-41.	1.7	30
105	Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat. European Journal of Pharmacology, 1991, 194, 45-49.	1.7	51
106	Inability of etonitazene and haloperidol to elicit conditioned taste aversion. Pharmacological Research, 1990, 22, 64.	3.1	0
107	Quantified EEG in different hypertensive rat strains and its modifications by oxiracetam (OXI). Pharmacological Research, 1990, 22, 17-18.	3.1	0
108	Central effect of yohimbine on sexual behavior in the rat. Physiology and Behavior, 1990, 47, 165-173.	1.0	47

#	Article	IF	CITATIONS
109	Oral opiate intake in a free-choice procedure in the rat. Pharmacological Research, 1989, 21, 67-68.	3.1	2
110	Supraspinal cerebral areas involved in morphine's intestinal inhibition and analgesia. Pharmacology Biochemistry and Behavior, 1988, 30, 319-324.	1.3	8
111	Further investigations on neurotensin as central modulator of intestinal motility in rats. Regulatory Peptides, 1987, 17, 111-117.	1.9	4
112	Intestinal effect and analgesia: Evidence for different involvement of opioid receptor subtypes in periaqueductal gray matter. European Journal of Pharmacology, 1986, 120, 95-99.	1.7	14
113	Cerebral sites of central action of dermorphin on intestinal motility in the rat. Peptides, 1985, 6, 149-153.	1.2	9
114	Central pharmacological activities and opiate receptor binding studies of some dermorphin analogs. Peptides, 1985, 6, 155-159.	1.2	31
115	Dermorphin interaction with peripheral opioid receptors. Neuropeptides, 1984, 5, 157-160.	0.9	18
116	Central and peripheral components of dermorphin's effect on rat intestinal propulsion in comparison to morphine. Peptides, 1983, 4, 55-58.	1.2	11
117	Effect on intestinal transit of neurotensin administered intracerebroventricularly to rats. Life Sciences, 1983, 33, 485-488.	2.0	11
118	Involvement of periaqueductal gray matter in intestinal effect of centrally administered morphine. European Journal of Pharmacology, 1983, 91, 251-254.	1.7	16
119	Increase of plasma corticosterone induced by loperamide in rats. European Journal of Pharmacology, 1982, 79, 101-104.	1.7	4
120	Effect of intracerebroventricular administration of morphine upon intestinal motility in rat and its antagonism with naloxone. European Journal of Pharmacology, 1977, 46, 329-338.	1.7	82
121	Liver tyrosine-alpha-ketoglutarate transaminase as a quantitative test of the phlogistic potency of agents topically applied. Pharmacological Research Communications, 1976, 8, 463-468.	0.2	1